Pharmacogenetic testing coverage by Canadian insurance providers

Area of Science:

• Pharmacogenomics
• Health Insurance Policy
• Clinical Genetics

Background:

• Access to pharmacogenetic (PGx) testing in Canada is restricted, often due to high costs outside research settings.
• Canadian insurance providers are beginning to cover PGx testing, but the specifics of this coverage are not well-defined.

Purpose of the Study:

• To systematically review publicly available PGx testing coverage policies from Canadian insurance companies.
• To evaluate eligibility criteria, affiliated laboratories, and the clinical utility of PGx test panels offered by insurers.

Main Methods:

• A systematic review of publicly accessible PGx coverage policies from ten Canadian insurance companies.
• Analysis of policy details including eligibility requirements, laboratory affiliations, and the scope of PGx panels.

Main Results:

• Six insurers offered partial reimbursement/discounts, while four had specific eligibility criteria (e.g., disability leave, physician diagnosis).
• Eligibility requirements were highly variable, and four commercial labs affiliated with insurers differed in the number of actionable genes/drugs tested.
• Substantial heterogeneity exists in insurer policies and lab test comprehensiveness, potentially leading to inequities in access and care quality.

Conclusions:

• Variability in insurance coverage for PGx testing may affect clinician recommendations and patient access to personalized therapies.
• There is a critical need for standardized PGx testing coverage policies and harmonized testing panels in Canada.
• Collaboration between insurers, researchers, and clinicians is vital for developing Canadian-specific evidence to guide equitable and effective PGx implementation.